Literature DB >> 3938396

Mitomycin C and vinblastine in the treatment of advanced breast cancer.

J A Radford, R K Knight, R D Rubens.   

Abstract

Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks. Eleven patients responded, giving a response frequency of 22%. Considering only the 40 patients evaluable after two or more courses of treatment, the response frequency is 27.5%. Responses occurred predominantly at soft tissue sites. Subjective toxicity was mild.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3938396     DOI： 10.1016/0277-5379(85)90241-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  6 in total

1.  Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.

Authors:  W Scheithauer; G Kornek; K Haider; W Kwasny; T Schenk; R Pirker; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.

Authors:  J Carmo-Pereira; F O Costa; E Henriques; F Godinho; M G Cantinho-Lopes; A Sales-Luis; R D Rubens
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

Review 3.  Drug repurposing for breast cancer therapy: Old weapon for new battle.

Authors:  Sadhna Aggarwal; Sumit Singh Verma; Sumit Aggarwal; Subash Chandra Gupta
Journal:  Semin Cancer Biol       Date:  2019-09-21       Impact factor: 15.707

Review 4.  Mouse Models and Tools for the in vivo Study of Neutrophils.

Authors:  Julien Stackowicz; Friederike Jönsson; Laurent L Reber
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561

5.  Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.

Authors:  A L Harris; J Carmichael; B M Cantwell; M Dowsett
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

6.  Chemotherapy of advanced breast cancer: outcome and prognostic factors.

Authors:  W M Gregory; P Smith; M A Richards; C J Twelves; R K Knight; R D Rubens
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.